Acrivon Therapeutics (NASDAQ:ACRV) CFO Acquires $15,014.40 in Stock

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) CFO Adam Levy purchased 8,832 shares of the firm’s stock in a transaction on Wednesday, January 14th. The shares were purchased at an average cost of $1.70 per share, with a total value of $15,014.40. Following the completion of the transaction, the chief financial officer owned 20,983 shares of the company’s stock, valued at approximately $35,671.10. The trade was a 72.69% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Acrivon Therapeutics Stock Up 5.9%

Shares of Acrivon Therapeutics stock opened at $1.98 on Monday. The company has a market cap of $62.49 million, a P/E ratio of -0.93 and a beta of 1.73. The firm’s 50 day moving average price is $2.30 and its 200-day moving average price is $1.83. Acrivon Therapeutics, Inc. has a 52-week low of $1.05 and a 52-week high of $8.00.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its earnings results on Thursday, November 13th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.10. As a group, equities research analysts forecast that Acrivon Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. UBS Group AG boosted its position in Acrivon Therapeutics by 150,057.8% in the 3rd quarter. UBS Group AG now owns 683,218 shares of the company’s stock worth $1,237,000 after purchasing an additional 682,763 shares in the last quarter. Two Sigma Investments LP lifted its stake in shares of Acrivon Therapeutics by 76.2% in the 3rd quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock valued at $578,000 after purchasing an additional 138,033 shares during the period. Jane Street Group LLC purchased a new stake in Acrivon Therapeutics during the second quarter worth $371,000. XTX Topco Ltd purchased a new stake in Acrivon Therapeutics during the second quarter worth $126,000. Finally, Algert Global LLC acquired a new stake in Acrivon Therapeutics during the third quarter valued at $81,000. 71.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on ACRV shares. Piper Sandler increased their price target on Acrivon Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. Wall Street Zen downgraded shares of Acrivon Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Acrivon Therapeutics in a research note on Monday, December 29th. Finally, HC Wainwright reissued a “buy” rating and set a $19.00 target price on shares of Acrivon Therapeutics in a research report on Tuesday, November 25th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $11.67.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.